has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens RNA vaccine intramuscular route therapeutic vaccine function vaccine in clinical trial role RNA vaccine role therapeutic cancer vaccine KRAS-targeted mRNA vaccine 6348 A cancer vaccine used alone or in combination with PD-1 inhibitor in patients with advanced solid tumors with KRAS mutation (G12C, G12D, or G12V) and HLA type HLA-A11:01 or HLA C08:02. The vaccine is a lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets the most commonly occurring KRAS mutations (G12D, G12V, and G12C). The mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. Jie Zheng NCT: https://clinicaltrials.gov/study/NCT05202561 cancer vaccine Hayleigh Kahn VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6348 Gene name: KRAS 3845 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186